Receptor, Platelet-Derived Growth Factor alpha
"Receptor, Platelet-Derived Growth Factor alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A PDGF receptor that binds specifically to both PDGF-A chains and PDGF-B chains. It contains a protein-tyrosine kinase activity that is involved in SIGNAL TRANSDUCTION.
| Descriptor ID |
D020796
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.900.500 D12.776.543.750.630.625.300 D12.776.543.750.750.400.630.300
|
| Concept/Terms |
Receptor, Platelet-Derived Growth Factor alpha- Receptor, Platelet-Derived Growth Factor alpha
- Platelet-Derived Growth Factor alpha Receptor
- Platelet Derived Growth Factor alpha Receptor
- Antigens, CD140a
- PDGFRalpha
- PDGF-R-alpha
- Receptor, PDGF alpha
- CD140a Antigen
- Antigen, CD140a
- PDGFR2
- PDGF alpha Receptor
- CD140a Antigens
|
Below are MeSH descriptors whose meaning is more general than "Receptor, Platelet-Derived Growth Factor alpha".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- Receptors, Platelet-Derived Growth Factor [D08.811.913.696.620.682.725.400.900]
- Receptor, Platelet-Derived Growth Factor alpha [D08.811.913.696.620.682.725.400.900.500]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
- Receptors, Platelet-Derived Growth Factor [D12.776.543.750.630.625]
- Receptor, Platelet-Derived Growth Factor alpha [D12.776.543.750.630.625.300]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- Receptors, Platelet-Derived Growth Factor [D12.776.543.750.750.400.630]
- Receptor, Platelet-Derived Growth Factor alpha [D12.776.543.750.750.400.630.300]
Below are MeSH descriptors whose meaning is more specific than "Receptor, Platelet-Derived Growth Factor alpha".
This graph shows the total number of publications written about "Receptor, Platelet-Derived Growth Factor alpha" by people in this website by year, and whether "Receptor, Platelet-Derived Growth Factor alpha" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 3 | 1 | 4 |
| 2021 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, Platelet-Derived Growth Factor alpha" by people in Profiles.
-
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study. Clin Cancer Res. 2021 12 01; 27(23):6333-6342.
-
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol. 2021 10 01; 39(28):3128-3139.
-
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer. 2021 03; 145:132-142.
-
Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. Oncologist. 2021 04; 26(4):e622-e631.
-
Secreted Protein Acidic and Cysteine Rich Matricellular Protein is Enriched in the Bioactive Fraction of the Human Vascular Pericyte Secretome. Antioxid Redox Signal. 2021 05 20; 34(15):1151-1164.
-
Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. Mol Cancer Ther. 2021 01; 20(1):132-141.
-
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. J Clin Oncol. 2020 10 01; 38(28):3294-3303.
-
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020 07; 21(7):935-946.
-
Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors. Future Oncol. 2020 Aug; 16(22):1639-1646.
-
Olaratumab in soft tissue sarcoma - Current status and future perspectives. Eur J Cancer. 2018 03; 92:33-39.